Human Immunology News 7.35 September 10, 2019 | |
| |
TOP STORYTo understand the basis of the anti-drug antibody (ADA) response and the mechanism of ADA-mediated neutralization, scientists performed an in-depth analysis of the B and T cell responses in two patients. They found that, in both patients, the response was polyclonal and targeted different epitopes of the natalizumab idiotype. [Nat Med] Abstract | |
| |
PUBLICATIONS(Ranked by impact factor of the journal)Neutrophils from the peripheral blood of patients with hidradenitis suppurativa (HS) peripheral displayed enhanced spontaneous neutrophil extracellular trap (NET) formation when compared to healthy control neutrophils. Sera from patients recognized antigens present in NETs and harbored increased antibodies reactive to citrullinated peptides. B cell dysregulation, as evidenced by elevated plasma cells and IgG, was observed in the circulation and skin from patients with HS. [Sci Transl Med] Abstract CXCR1- or CXCR2-Modified CAR T Cells Co-Opt IL-8 for Maximal Antitumor Efficacy in Solid Tumors Scientists demonstrated that IL-8 receptor, CXCR1 or CXCR2, modified chimeric antigen receptors (CARs) markedly enhanced migration and persistence of T cells in the tumor, which induced complete tumor regression and long-lasting immunologic memory in pre-clinical models of aggressive tumors such as glioblastoma, ovarian and pancreatic cancer. [Nat Commun] Full Article The expression of pre-B-cell leukemia homeobox 1 (PBX1) was significantly higher in chronic myeloid leukemia (CML) CD34+ cells than that in control cells and PBX silencing inhibited the growth of CML cells and sensitized them to imatinib treatment. [Oncogene] Abstract Alum decreased PD-L1 expression and IL-10 production induced by mannan (PM) in human dendritic cells (DCs) and increased pro‐inflammatory cytokine production. Alum impaired PM-induced functional FOXP3+ Treg cells and promoted Th1/Th2/Th17 responses. [Allergy] Abstract High CD3+, CD4+ and FOXP3+ T-cell densities were associated with improved relapse-free survival; high CD8+, CD4+ and FOXP3+ T-cell densities were associated with improved disease-specific survival. [Br J Cancer] Abstract Hypoxia exacerbated monocyte-derived CCL20 and IL-1β release in response to LPS, and increased glycolytic intermediates at the expense of carnitines. Modulation of carnitine identified a novel role for fatty acid oxidation in the production of CCL20 in response to LPS. [Rheumatology (Oxford)] Abstract Scientists found that immunoproteasome inhibition with the irreversible LMP7/LMP2 inhibitor ONX 0914 induced apoptosis in CD14+ monocytes, whereas CD4+, CD3+, CD19+, and CD56+ cells remained unaffected. [J Immunol] Abstract Researchers evaluated the effect of the omega-3 polyunsaturated fatty acid docosahexaenoic acid on antioxidant defence in macrophages from patients with abdominal aortic aneurysm. [Sci Rep] Full Article G-CSF and GM-CSF Modify Neutrophil Functions at Concentrations found in Cystic Fibrosis Investigators assessed granulocyte-colony stimulating factor (CSF) and granulocyte-macrophage-CSF levels in cystic fibrosis patients in various clinical conditions and how these cytokines impact on activation and priming of neutrophils. [Sci Rep] Full Article Subscribe to our sister publications: Immunology of Infectious Disease News & Immune Regulation News. | |
| |
REVIEWSTranslating Gammadelta (γδ) T Cells and Their Receptors into Cancer Cell Therapies Scientists discuss the challenges and opportunities for the clinical implementation of cancer immunotherapies based on γδT cells and their receptors. [Nat Rev Drug Discov] Abstract Bedside to Bench: Defining the Immunopathogenesis of Psoriatic Arthritis Investigators review data utilizing various novel targeted therapies for psoriatic arthritis, focusing on biologic and targeted synthetic therapies. [Nat Rev Rheumatol] Abstract Visit our reviews page to see a complete list of reviews in the human immunology research field. | |
| |
INDUSTRY NEWSBe The Match BioTherapies® and Celyad announced a collaboration to advance the clinical trial of Celyad’s non-gene edited allogeneic CAR-T therapies. [Be The Match BioTherapies®] Press Release Phio Pharmaceuticals Corp. announced that it has entered into a research collaboration with Carisma Therapeutics to evaluate the potential of Phio’s self-delivering RNAi compounds to synergistically modify Carisma’s chimeric antigen receptor macrophages. [Phio Pharmaceuticals Corp.] Press Release Merck announced the initiation of two global pivotal Phase III trials studying the efficacy and safety of evobrutinib, an oral, highly selective Bruton’s tyrosine kinase inhibitor in adult patients with relapsing multiple sclerosis. [Merck (Business Wire, Inc.)] Press Release Lipidor AB reported that the last patient has been enrolled in the ongoing Phase III study using calcipotriol spray against mild to moderate psoriasis. [Lipidor AB (PR Newswire Association LLC.)] Press Release | |
| |
POLICY NEWSElsevier Investigates Hundreds of Peer Reviewers for Manipulating Citations The Dutch publisher Elsevier is investigating hundreds of researchers whom it suspects of deliberately manipulating the peer-review process to boost their own citation numbers. [Nature News] Editorial Frontrunner to Lead FDA, Dogged by Controversies, Has Developed Knack for Confronting Them Before he interviewed with President Trump to become FDA commissioner, Dr. Stephen Hahn had only been here once in a formal capacity: to apologize to Congress. [STAT News] Editorial Northwestern University Stem Cell Therapy Clinic Closes Abruptly A pioneering stem cell clinical trial program in the US is closing up shop, a surprise move for what had appeared to be a successful endeavor at testing hematopoietic stem cell transplantations for autoimmune and other diseases. [STAT News] Editorial Google Bans Ads for Experimental Medical Treatments Google announced it would “prohibit advertising for unproven or experimental medical techniques such as most stem cell therapy, cellular (non-stem) therapy, and gene therapy.” [STAT News] Editorial
| |
EVENTSNEW Cell Death in Immunity and Inflammation Visit our events page to see a complete list of events in the community.
| |
JOB OPPORTUNITIESNEW Postdoctoral Researcher – Human Immunology (University of Gothenburg) Research Technologist (STEMCELL Technologies Inc.) Scientific Communications Coordinator (STEMCELL Technologies Inc.) Scientist – Human Immunology (STEMCELL Technologies Inc.) Research Associate – Immune Cell Culture (STEMCELL Technologies Inc.) Postdoctoral Position – Stem Cell Biology and Immunology (Columbia University) Postdoctoral Research Associate – Autoimmune Diseases (Benaroya Research Institute) Senior Scientific Researcher – Inflammatory Diseases (Genentech, Inc.) Research Assistant – Immunology (MD Anderson Cancer Center) Postdoctoral Position – Immunology (BioMed X Innovation Center) Preclinical Scientist – Immunology (MiroBio) Postdoctoral Position – Immunology of Enteric Infections (University of Utah) Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
| |
Have we missed an important article or publication in Human Immunology News? Click here to submit! Comments or suggestions? Submit your feedback here. | |
|